Phase 2 Glaucoma Trial, Recruiting (NCT06223048)

Phase 2 Glaucoma Trial, Recruiting NCT06223048 Sponsor: Amydis Inc. Condition: Glaucoma

Printed from Voxsanity (voxsanity.com.au) — NCT06223048 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Glaucoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a specific type of glaucoma called primary open angle glaucoma in both eyes
You are able to focus your gaze steadily (fixate) during an eye exam
A doctor has confirmed that both of your eyes show signs of glaucoma-related damage to the optic nerve (the nerve connecting your eye to your brain)

Who may not be able to join:

You are unable to read or write
The inside of your eyes cannot be photographed clearly enough due to cloudiness or other issues (confirm with trial site)
You have any other eye condition besides glaucoma in the eye being studied — though cataracts are an exception and would still allow you to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: David Bingaman, Amydis Inc.

Phone: 858-254-7435

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06223048

Sponsor: Amydis Inc.

Phase: Phase 2

Status: Recruiting

Condition: Glaucoma

Trial contact: 858-254-7435

More information: https://clinicaltrials.gov/study/NCT06223048

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a specific type of glaucoma called primary open angle glaucoma in both eyes
You are able to focus your gaze steadily (fixate) during an eye exam
A doctor has confirmed that both of your eyes show signs of glaucoma-related damage to the optic nerve (the nerve connecting your eye to your brain)

Who may not be able to join:

You are unable to read or write
The inside of your eyes cannot be photographed clearly enough due to cloudiness or other issues (confirm with trial site)
You have any other eye condition besides glaucoma in the eye being studied — though cataracts are an exception and would still allow you to participate

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Amydis Inc.

Registry

ClinicalTrials.gov

Start date

7 December 2023

Est. completion

1 November 2024

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

AMDX-2011P Adverse Events Profile

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov